瑞舒伐他汀对冠心病合并 2 型糖尿病患者血浆 Omentin -1 的影响简

目的探讨冠心病（CHD）合并2型糖尿病（T2DM）患者血浆网膜素-1（Omentin-1）水平的变化及瑞舒伐他汀治疗对Omentin-1水平的影响。方法选择临床确诊的住院和门诊单纯T2DM患者42例和CHD合并T2DM患者47例。同期选择健康体检者37例作为正常对照组（NC组）。采用ELISA法测定所有研究对象及CHD合并T2DM组瑞舒伐他汀治疗后血浆Omentin-1水平，并分析血浆Omentin-1水平与白细胞介素6（IL-6）、空腹胰岛素（FINS）、体重指数（BMI）、内皮素（ET）、胰岛素抵抗指数（HOMA-IR）和-氧化氮（NO）等的关系。结果与NC组（24．79±6．18ng／m1）比较，CHD合并T2DM组治疗前（14．75±4．02ng／m1）和单纯T2DM组（19．32±5．17ng／m1）患者血浆Omentin-1水平均明显降低（P均〈0．01），CHD合并T2DM组治疗前血浆Omentin-1水平显著低于单纯T2DM组（14．75±4．02V8．18．30±5．17ng／ml，P〈0．01）。CHD合并T2DM患者血浆Omentin-1水平与FINS、BMI、HOMA—IR、IL-6、ET呈明显负相关，与NO呈正相关（P〈0．01或P〈0．05）。HOMA-IR、IL-6和NO是影响CHD合并T2DM患者血浆Omentin-1水平的独立相关因素。CHD合并T2DM患者经瑞舒伐他汀治疗后TC、LDL-C、IL-6和ET均显著降低，而HDL—C和NO则显著增高（P〈0．05），同时血浆Omentin-1水平也明显升高（18．35±3．97vs．14．75±4．02ng／ml，P〈0．01）。结论瑞舒伐他汀在有效调节CHD合并T2DM患者脂代谢，减轻炎症反应，改善内皮功能的同时，升高血浆Omentin-1水平。

Effects of rosuvastatin on plasma omentin - 1 levels in coronary heart disease patients with type 2 diabetes mellitus.

Objective To explore the effects of rosuvastatin on plasma omentin - 1 levels in coronary heart disease （CHD） patients with type 2 diabetes mellitus （T2DM）. Methods Forty -two patients with uncomplicated T2DM, 47 CHD patients accompanied with T2DM and 37 subjects with normal control （NC） participated in this study. The relationship between plasma omentin - 1 levels and interleukin - 6 （ IL - 6 ）, body mass index （ BMI）, endothelin （ ET）, HOMA - insulin resistance index （ HOMA - IR）, nitric oxide （NO） was analyzed. After rosuvastatin treatment, plasma omentin - 1 levels were observed in CHD patients with T2DM. Results Patients with T2DM and CHD patients complicated by T2DM before the treatment had significantly lower plasma omentin - 1 levels than that of NC group （ 19.32 ± 5.17 vs. 24.79 ± 6.18 ng/ml and 14.75 ± 4.02 vs. 24.79 ± 6.18 ng/ml, respectively, all P 〈 0.01 ）. CHD patients complicated by T2DM before the treatment had significantly lower plasma omentin - I levels than that of T2DM group （ 14.75 ± 4.02 vs. 18.30 ± 5.17 ng/ml, P 〈 0.01 ）. Plasma omentin - 1 levels were negatively correlated with fasting insulin （ Fins）, BM1, HOMA - IR, IL - 6 and ET and positively correlated with NO （ P 〈 0.01 or P 〈 0.05 ）. HOMA - IR, IL - 6 and NO were the independent risk factors of plasma omentin - 1 in CHD patients complicated by T2DM. After rosuvastatin treatment, total cholesterol （ TC）, low - density lipopretein cholesterol （ LDL - C）, IL - 6 and ET were significantly decreased, and high - densi- ty lipoprotein cholesterol （HDL -C） and NO levels were significantly increased （ P 〈 0.05 ） in CHD patients complicated by T2DM. Moreover, plasma omentin - 1 levels were also significantly increased （ 18.35 ± 3.97 vs. 14.75 ± 4.02 ng/ml, P 〈 0.01 ）. Conclusion Rosuvastatin can remarkably regulate lipid metabolism, reduce inflammatory reaction, improve endothelial function as well as elevate plasma omentin - 1 levels in CHD patients complicated by T2DM.